Best of ASCO - 2014 Annual Meeting

 

Welcome

Value/Cost of Care

Health Services Research, Clinical Informatics, and Quality of Care

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma.

Ambika Parmar

6639

A process to reduce hospital admissions in the OCM population through focused intervention of super-utilizers.

Manuel Perry

6505

A weighted criterion-based approach to value assessment of oncology drugs.

Doreen Anuli Ezeife

6627

Acute kidney injury in childhood cancer: An insight from Kids' Inpatient Database.

Eman M Elsabbagh

e18379

Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017) in TRANSCEND NHL 001.

Jeremy S. Abramson

6637

Clinical and economic outcomes of pegfilgrastim in metastatic colorectal cancer.

Lalan S. Wilfong

6636

Clinical benefit and prices of cancer drugs in the United States and Europe.

Kerstin Noëlle Vokinger

6638

Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting.

Sienna Durbin

6634

Community oncologists perceptions and readiness to implement Medicare Access and CHIP Reauthorization Act (MACRA).

Bela Bapat

e18374

Cost and time savings of subcutaneous trastuzumab (SC-T) in a public health system in Mexico.

Cynthia Villarreal-Garza

e18387

Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada.

Ying Wang

6629

Cost effectiveness (CE) of blinatumomab (BLIN) versus inotuzumab ozogamicin (INO) in adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) with no more than one prior salvage therapy (S0/S1) from a United Kingdom health care perspective.

Thomas E. Delea

e18359

Cost effectiveness of updated laboratory monitoring schedule for immunotherapy regimes.

Karine Ronan

e18363

Cost of oral cancer drugs: Trends in the United States Medicare population in 2013 and 2015.

Kira Rose-Madison Seiger

6631

Cost-effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal cancer.

Afsaneh Barzi

e18367

Cost-effectiveness of CHOP in treating DLBCL in Malawi.

Matthew Painschab

6644

Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.

Shaji Kumar

e18356

Cost-effectiveness of primary prophylaxis with pegfilgrastim in early-stage breast cancer patients receiving chemotherapy in China.

Wen Xia

e18349

Cost-effectiveness of programmed cell death protein 1/programmed death-ligand 1 inhibitors (aPD1/aPDL1) varies widely.

Benjamin P Geisler

e18351

Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (Febrile) neutropenia and expanded access based on budget neutral basis.

Weijia Wang

6645

Cost-minimization analysis of using tumor cell-free DNA as monitoring tool in cancer immunotherapy.

Alexander Kuhlmann

6642

Crowdfunding for lung cancer costs.

Ryan Nguyen

e18340

Demographic factors associated with financial toxicity: Results from the multisite cost study.

Divya Ahuja Parikh

e18362

Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC).

Veena Shankaran

TPS6652

Desire to address costs at time of treatment decisions among patients with metastatic breast cancer.

Yvonne Y. Lei

6640

Do the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale measure Absolute or Relative clinical benefit?

Ronak Saluja

e18378

Drug funding price negotiations: Towards achieving a balance between individual and population gains in health benefits.

Ambika Parmar

6641

Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.

Evan Thomas Hall

6504

Economic analysis of ceritinib used as second-line versus third-line treatment for patients with ALK-rearranged non-small-cell lung cancer.

Bin Wu

e18355

Economic benefits of adaptive abiraterone therapy for advanced prostate cancer.

Neil Thomas Mason

e18343

Economic burden of immunotherapy as second-line treatment of patients with advanced non-small-cell lung cancer at a Latin American oncology center.

Feliciano Barron Barron

e18376

Economic impact of post-progression treatment in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously treated with octreotide monotherapy.

David Ray

e18366

Economic impact of the 31-gene expression profile test in the Medicare-eligible population with cutaneous melanoma.

Federico A. Monzon

6630

Efficacy and cost-effectiveness of HER2+ early breast cancer therapies.

Marcos Fonseca Magalhães Filho

e18380

Efficacy of a stepped collaborative care intervention for comorbid cancer and depression: Health care utilization and costs.

Geena Richards

e18348

Evaluating the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) value frameworks for Food and Drug Administration (FDA) approved checkpoint inhibitors (CIs).

Sophie Feng

6624

Fear of receiving less effective care: A barrier to effective cancer care cost communication.

Sokbom Kang

e18339

Followup mammography after breast conservation therapy: Is 3D Tomosynthesis(3DT) worth it?

Shaakir Hasan

6628

Frequency and causes of oncologists’ burnout in community practices.

Chadi Nabhan

e18375

How will the cost of biosimilars affect patients’ willingness to receive them?

R Donald Harvey

e18338

Identifying and predicting the most costly patients in oncology.

Mark Raymond Waddle

6633

Impact of solid tumor brain metastases on end-of-life healthcare utilization.

Emily Miller Ray

e18373

Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?

Naomi RM Schwartz

6625

Modeling an oncology outcomes-based contract using a blockchain database approach: Cost and technology considerations.

Jennifer M. Hinkel

e18360

Monthly parts a and b costs by service and line of therapy for FDA-approved/NCCN category 1 treatments for patients with metastatic pancreatic cancer.

L. Daniel Muldoon

e18365

National cancer expenditure analysis in the United States Medicare population, 2013.

Emily S Ruiz

6647

Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials.

Ryan Huey

e18383

Patterns of healthcare utilization in patients with newly diagnosed advanced lung cancer.

Emily Miller Ray

e18386

Perspectives and practices of oncology providers in addressing financial toxicity.

Meera Vimala Ragavan

e18342

Pharmacy cost in cancer.

Surbhi Shah

e18358

Predictors of financial toxicity among head and neck cancer patients: A prospective cohort study.

John R. de Almeida

e18361

Progression free survival (PFS) benefits of immuno-oncology agents (IOs) and implications for market cost-sharing inefficiencies.

Syed Muhammad Mushtaq Ashraf

6643

Projecting overall survival data for health-economic models in oncology: Do maturity levels impact uncertainty?

Stéphane Roze

e18350

Proper dosage of primary pegylated G-CSF prophylactic use for breast cancer patients receiving adjuvant or neo-adjuvant chemotherapy.

Liang Yu

e18354

Quantification of the financial burden of antineoplastic agent price increases.

Michail Alevizakos

6519

Real-world demographic and clinical characteristics of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in the United States (US).

Xiaoqin Yang

e18347

Relationship of emergency department use pre- and post-cancer diagnosis in safety-net adults.

Arthur Hong

6626

Role of advanced practice providers (APP) in meeting rising demands on oncology practices.

Bela Bapat

e18372

Scope of practice of advanced practice providers (APP) in US community oncology.

Andrew Klink

6646

Social values and cancer funding priorities: Empirical evidence for cancer policy.

Avram Denburg

e18352

Sustaining the gains in cancer care from the oncology care model.

Valerie P Csik

6632

The ability of isolated fine needle aspiration of lymph nodes to provide complete diagnostic information without necessitating additional diagnostic procedures: A retrospective cohort study.

Nathan Tidwell

e18341

The effect of guideline-concordant novel therapy use on meeting cost targets in OCM: Results from a large community oncology network.

Stephen Matthew Schleicher

6635

The financial impact of fractionation scheme and treatment planning method for rectal cancer in the United States.

Assaf Moore

6518

The financial impact of physician practice patterns: An analysis of as-needed filgrastim versus prophylactic pegfilgrastim in patients with prostate cancer receiving docetaxel.

Christine Barrett

6506

Total cost of care for patients (pts) with stage II colon cancer (CC-II): A SEER-Medicare analysis.

Afsaneh Barzi

6648

Treatment patterns, survival rate, and Parts A and B costs by line of therapy for FDA-approved/NCCN Category 1 treatments for patients with metastatic pancreatic cancer.

L. Daniel Muldoon

e18357

Trends in financial relationships between industry and individual medical oncologists in the United States from 2014 to 2017: A cohort study.

Deborah Catherine Marshall

6520

Understanding differences in total cancer care cost by service site.

Karen K. Fields

e18345

Use of a modified Delphi panel to define value of combination therapy in oncology.

Michael Broder

e18369

Utility of tumor genomic profiling in guiding targeted therapy and referral for clinical trials in the community practice.

Yiqing Xu

e18381

Value appraisal of FDA approved cancer drugs over the past decade.

Ryan Huey

e18385